Literature DB >> 656822

Stilboestrol and vaginal clear-cell adenocarcinoma syndrome.

J M Monaghan, L A Sirisena.   

Abstract

A vaginal clear-cell adenocarcinoma developed in a young woman who had been exposed in utero to maternal stilboestrol treatment. During 1940-71 in the UK some 7500 women were given stilboestrol during pregnancy. Thus more cases are likely to appear and clinicians caring for young women should be alert to this possibility.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656822      PMCID: PMC1605413          DOI: 10.1136/bmj.1.6127.1588

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  1 in total

1.  Epidemiology of vaginal adenosis and adenocarcinoma associated with exposure to stilbestrol in utero.

Authors:  D C Poskanzer; A L Herbst
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

  1 in total
  6 in total

1.  The daughters of stilboestrol.

Authors:  M Wingfield
Journal:  BMJ       Date:  1991-06-15

Review 2.  Exogenous hormones in the aetiology of cancer in women.

Authors:  M P Vessey
Journal:  J R Soc Med       Date:  1984-07       Impact factor: 5.344

3.  Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent.

Authors:  Hiromitsu Yabushita; Kouhei Kanyama; Rinko Sekiya; Mari Noguchi; Akihiko Wakatsuki
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

4.  Admissions to hospital of children with sickle-cell anaemia: a study in south London.

Authors:  L N Murtaza; C E Stroud; L R Davis; D J Cooper
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-28

5.  Randomised trial of high doses of stilboestrol and ethisterone therapy in pregnancy: long-term follow-up of the children.

Authors:  V Beral; L Colwell
Journal:  J Epidemiol Community Health       Date:  1981-09       Impact factor: 3.710

Review 6.  Aetiology of gynaecological cancer.

Authors:  G Chamberlain
Journal:  J R Soc Med       Date:  1981-04       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.